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Abstract
Background: The dual-bolus protocol enables accurate quantification of myocardial blood flow (MBF) by first-pass
perfusion cardiovascular magnetic resonance (CMR). However, despite the advantages and increasing demand for
the dual-bolus method for accurate quantification of MBF, thus far, it has not been widely used in the field of
quantitative perfusion CMR. The main reasons for this are that the setup for the dual-bolus method is complex and
requires a state-of-the-art injector and there is also a lack of post processing software. As a solution to one of these
problems, we have devised a universal dual-bolus injection scheme for use in a clinical setting. The purpose of this
study is to show the setup and feasibility of the universal dual-bolus injection scheme.
Methods: The universal dual-bolus injection scheme was tested using multiple combinations of different contrast
agents, contrast agent dose, power injectors, perfusion sequences, and CMR scanners. This included 3 different
contrast agents (Gd-DO3A-butrol, Gd-DTPA and Gd-DOTA), 4 different doses (0.025 mmol/kg, 0.05 mmol/kg, 0.075
mmol/kg and 0.1 mmol/kg), 2 different types of injectors (with and without “pause” function), 5 different
sequences (turbo field echo (TFE), balanced TFE, k-space and time (k-t) accelerated TFE, k-t accelerated balanced
TFE, turbo fast low-angle shot) and 3 different CMR scanners from 2 different manufacturers. The relation between
the time width of dilute contrast agent bolus curve and cardiac output was obtained to determine the optimal
predefined pause duration between dilute and neat contrast agent injection.
Results: 161 dual-bolus perfusion scans were performed. Three non-injector-related technical errors were observed
(1.9%). No injector-related errors were observed. The dual-bolus scheme worked well in all the combinations of
parameters if the optimal predefined pause was used. Linear regression analysis showed that the optimal duration
for the predefined pause is 25s to separate the dilute and neat contrast agent bolus curves if 0.1 mmol/kg dose of
Gd-DO3A-butrol is used.
Conclusion: The universal dual-bolus injection scheme does not require sophisticated double-head power injector
function and is a feasible technique to obtain reasonable arterial input function curves for absolute MBF
quantification.
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First-pass myocardial perfusion cardiovascular magnetic
resonance (CMR) uses a series of T1-weighted images
during the passage of a contrast bolus through the heart
to characterize myocardial blood flow (MBF). The use
of fully quantitative analysis of first-pass myocardial per-
fusion CMR allows the absolute quantification of MBF
in units of ml/min/g and may permit an accurate, objec-
tive assessment of altered myocardial perfusion in
patients with heart disease (1-3). Accurate MBF quanti-
fication by myocardial first-pass perfusion CMR relies
on a linear relationship between signal intensity and
gadolinium concentration. However, it is well-known
that with gadolinium concentrations currently in use for
first-pass perfusion MR imaging, T1-saturation effects
can cause substantial signal attenuation predominantly
in the left ventricular (LV) cavity where the signal inten-
sity-time curve usually represents the arterial input
function (AIF) (3, 4). To preserve an accurate AIF, pre-
vious studies using quantitative measures have focused
on low doses (0.025 mmol/kg-0.05 mmol/kg) of contrast
agent in combination with strongly T1 weighted
sequences(1, 5). Low-dose techniques are applied for
precise and reproducible absolute quantification of car-
diac perfusion(1, 5). However, this approach is limited
by a low contrast to noise ratio (CNR) in the myocardial
tissue as a result of limited myocardial enhancement.
To overcome the limitation of T1-induced MR signal
saturation in the LV blood pool and low CNR in the myo-
cardial tissue, dual-bolus first-pass perfusion CMR meth-
ods were recently introduced to allow the use of high
gadolinium concentration contrast for myocardial analysis,
and a lower gadolinium concentration bolus to maintain
the linearity of the LV signal intensity (6-10). These tech-
niques use a low dose of dilute contrast agent as a prebo-
lus before the main bolus of neat contrast agent.
Clinically important issues in the dual-bolus protocol
are that:
1) Both the main-bolus of neat gadolinium contrast
agent (CA), and the pre-bolus of diluted gadolinium
CA solution, should be of equal volume and admi-
nistered at the same flow rate(6, 7).
2) Each bolus should be followed by a saline flush to
maintain a compact CA bolus in the LV chamber.
Each bolus should also be equal in volume and
administered at the same rate(6-9).
3) The time delay between each bolus of CA can be
controlled to minimize temporal overlap, this delay
can be also adjusted to heart rate if required(6-8),
4) The system should be easy to set up
5) The procedure is easy to perform and repeat
within a routine clinical scan.
The dual-bolus protocol enables accurate quantifica-
tion of MBF by first-pass myocardial perfusion CMR
(9). However, despite the advantages and increasing
demand for the dual-bolus method for accurate quantifi-
cation of MBF(11), thus far, it has not been widely used
in the field of quantitative perfusion CMR. The main
reasons for this are that the setup for the dual-bolus
method is complex and requires a state-of-the-art injec-
tor and also there is a lack of post processing software.
As a solution to one of these problems, we have devised
a universal dual-bolus injection scheme that does not
require a sophisticated double-head power injector and
can be easily employed in a clinical setting. The purpose
of this study is to show the set-up and feasibility of the
universal dual-bolus injection scheme.
Methods
Set-up for the universal dual-bolus injection scheme
The set-up for the universal dual-bolus injection scheme
is described as a step-by-step protocol as follows.
For injectors with a programmable “pause” func-
tionality (Figure 1, 2 and 3)
Step1 (Preparation of gadolinium CA) (Figure 1A)
1. Draw 1 ml of gadolinium CA into a 10 ml syringe
(syringe 1) and dilute it to a 10% solution by adding
9 ml of saline. Repeat this process for syringe 2.
2. Adjust the volume of syringe1 and syringe 2
according to the weight of the patient i.e. if a 60 kg
patient needs 6 ml of 1.0 mol/L gadolinium CA then
discard 4 ml of CA from 10 ml syringe (syringe 1 and
2 therefore consist of 10% dilute gadolinium CA).
3. Draw the same volume of neat gadolinium CA
into two additional 10 ml syringes (syringe 3 and
4 therefore consist of neat gadolinium CA).
Note: These two pairs of syringes containing 10%-dilute
and neat gadolinium CA are used for the stress and rest
bolus injection respectively. It is possible to substitute lar-
ger or smaller syringes adapted to the dose of contrast
medium. All syringes should be carefully labelled.
Step 2 (Preparation of injector and tubing) (Figure 1B
and 2A)
1. Fill both the first (A) and second (B) power injec-
tor syringes with at least 60 ml of saline.
2. Connect Y-shaped long tube to injector syringes
as per the manufacturer’s instructions.
3. Connect a three-way stopcock (stopcock A) to the
distal end of the Y-shaped long tube.
4. Connect a high-pressure extension tube with
15 ml volume to stopcock A.
5. Flush these tubes with saline
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see the text for details.
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Page 3 of 136. Connect the distal end of the high-pressure
extension tubes to a venous cannula in the patient’s
antecubital vein.
Step 3 (Programming the dual-head power injector)
(Figure 3A).
1. Injector A (first phase): Set the flow rate to 4 ml/s
and the volume of saline flush to 25 ml).
2. Injector A (second phase): To program the delay
time between the pre-bolus and the main-bolus,
use the “pause” phase and set the desired time
delay.
3. Injector B: Set the flow rate and volume of the
saline injection as for injector A.Step 4 (Loading the
gadolinium CA and dual-bolus injection)
1. Connect the 10 ml syringe containing dilute CA
(syringe 1) to stopcock A without injecting the CA
(Figure 1B).
2. Once the set up for the perfusion scan is ready,
arm the injector.
3. Just prior to the power injection turn stopcock A
and manually inject the entire volume of dilute CA
(syringe 1) into the high-pressure extension tube
(Figure 1C and 1D).
Figure 2 A dual-head power injector and tubing set-up for a perfusion CMR in the case of the dual-head power injector with and
without a “pause” function (A and B respectively). Please see the text for details.
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Page 4 of 134. Disconnect the syringe 1 (dilute CA) and connect
the 10 ml syringe containing neat CA (syringe 3) to
stopcock A without injecting the CA (Figure 1E).
5. Start the perfusion scan and the power injection
at the same time.
6. During the delay time, turn stopcock A and manu-
ally inject the entire volume of neat CA from the syr-
inge 3 (neat CA) into the high-pressure extension tube.
7. After the programmed delay, injection B (saline)
starts. This allows the contrast agent within the exten-
sion tube to be pushed into the patients (Figure 1F).
For injectors with no programmable “pause” func-
tionality (Figure 1, 2, 3 and 4)
Step1 (Preparation of gadolinium CA) (Figure 1A)
1.-3. All steps as described above.
Step 2 (Preparation of injector and tubing)(Figure 2B
and 4A)
1. Fill both the first (A) and second (B) power injec-
tor syringes with at least 60 ml of saline.
2. Connect a three-way stopcock (stopcock B) to the
tip of syringe A. This enables the attachment of a
syringe to act as a release mechanism for the addi-
tional saline injection, which is programmed to
allow a delay between dilute and neat CA. Connect
the empty 10 ml syringe to stopcock B (Figure 2B
a n d4 A ) .C o n n e c to n ea r mo ft h eY - s h a p e dl o n g
tube to stopcock B and the other arm of it to the tip
of syringe B.
3. -6. These steps as described above.
Step 3 (Programming the dual-head power injector)
(Figure 3B).
1. Injector A (first phase): Set the flow rate to 4 ml/s
and the volume of saline flush to 25 ml.
2. Injector A (second phase): As this injector does
not have a “pause” function, we need to set the flow
rate and volume of the saline injection, which will
allow a specific time delay. For example, for a 10s
delay, 1 ml volume at 0.1 ml/sec, for a 15s delay, 3
ml volume at 0.2 ml/sec, for a 20s delay, 2 ml
volume at 0.1 ml/s etc. This additional saline will
then be taken up into the “release” syringe, thereby
ensuring that there is no dilution of contrast agent,
which will be injected into the extension tube during
the delay.
3. Injector B: Set the flow rate and volume of the
saline injection as for injector A.Step 4 (Loading the
gadolinium CA and dual-bolus injection)
1. -6. These steps as described above (Figure 4B).
7. Just after injection A is completed (Figure 4C), turn
stopcock B to the empty 10 ml syringe in order to col-
lect the volume injected to define the pause (step3.2).
(Figure 4D).
8. -9. These steps as described above (Figure 4D).
During dynamic CMR image acquisition the patient is
instructed to breath gently as the first bolus is delivered
via the power injector and during the pause. The patient
is subsequently instructed to hold their breath whilst
the main bolus is delivered. Consequently each CA
bolus, of equal volume, is delivered to the patient at the
same flow rate with a pre-programmed temporal delay
between the dilute and neat bolus. A second dual-bolus
perfusion CMR acquisition can be performed by repeat-
ing step 3 and step 4.
Weight-adjusted dose of contrast agent
The volume of CA required for this method depends on
which particular CA is used (0.5 mol/L or 1.0 mol/L)
and on the desired dose of gadolinium CA. The dose of
gadolinium contrast agent is adjusted to the patient’s
weight. The current injection scheme has been devel-
oped for a 0.1 mmol/kg dose of Gd-DO3A-butrol
(Gadovist
®, Schering, Germany) (1.0 mol/L). In this
Figure 3 Programmed injector control in the case of the dual-
head power injector with (A) and without (B) a “pause”
function. Please see the text for details.
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Page 5 of 13Figure 4 Preparation of the dual-bolus injection scheme for injectors with no programmable “pause” functionality is illustrated. Please
see the text for details.
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Page 6 of 13setting, the volume of gadolinium CA required is less
than 10 ml for an average-sized individual. We, there-
fore, use 10 ml small syringes and 15 ml extension
tubes for the set-up described in this article. However,
with minor modifications (e.g. using shorter or longer
extension tubes and smaller or larger syringes), this
scheme can be applied to any type and dose of com-
monly used commercially available gadolinium CA.
Validation studies
Adenosine stress and/or rest dual-bolus perfusion CMR
were performed mainly in patients with known or sus-
pected coronary artery disease using the universal dual-
bolus injection scheme. For perfusion CMR, three short
axis slices were acquired every heart beat for a period
lasting 70 heartbeats using one of the following non-
slice-selective saturation-recovery perfusion sequences;
turbo field echo (TFE)/turbo fast low-angle shot (Turbo-
FLASH), balanced TFE, k-space and time (k-t) acceler-
ated TFE and k-t accelerated balanced TFE (Table 1). In
addition to these 4 different sequences, three different
contrast agents (Gd-DO3A-butrol (Gadovist
®, 1 mol/L,
Schering, Germany), Gd-DTPA (Magnevist
®, 0.5 mol/L,
Schering, Germany) and Gd-DOTA (Dotarem
®,0 . 5
mol/L, Laboratoire Guerbet, France)), 4 different doses
(0.025 mmol/kg, 0.05 mmol/kg, 0.075 mmol/kg, 0.1
mmol/kg), 2 different injectors (with and without
“pause” function; Spectris
® and Spectris Solaris
® EP,
respectively; MEDRAD, INC., USA) and 3 different MR
scanners from 2 different manufacturers (Philips
Achieva and Intera; Siemens Avanto) were tested (Table
2). Dilution of the gadolinium contrast agent was per-
formed by a physician at each CMR session. The pre-
paration time for the dual-bolus set-up and heart rate at
rest and during adenosine stress was recorded. Stroke
volume (SV) and ejection fraction (EF) were determined
from standard short-axis cine MR images covering the
entire left ventricle using a balanced steady state free
precession (b-SSFP) sequence(12). Cardiac output at rest
and during stress was calculated as the stroke volume
multiplied by the heart rate at rest and during stress
respectively. In the current study, we didn’tp e r f o r ma
series of contiguous short axis cine MRI during adeno-
sine stress. Instead, we used the rest left ventricular
stroke volume (SV) to estimate the cardiac output (CO)
during stress as; COstress =S V rest ×H R stress,w h e r eH R
is heart rate. In this way, cardiac output during stress
can be overestimated. However, in terms of the purpose
of this study to validate the dual-bolus method setup,
this over estimation of stress cardiac output doesn’t
affect the overall results of our study, because the delay
time between pre-bolus and neat bolus is always less
during stress than in the resting state.
To test the feasibility of the dual-bolus set-up, we sent
a description of this dual-bolus method (i.e. the subsec-
tion entitled “Set-up for the universal dual-bolus injec-
tion scheme” in this paper) to 3 different sites in
different countries and asked them to perform perfusion
scans in 5 patients using these methods and predefined
pause of 25s.
Data analysis
Adenosine stress and rest perfusion CMR images were
analyzed using dedicated software (CMR 42; Circle Cardi-
ovascular Imaging Suite 12, Calgary, Alberta, Canada). On
a representative image from the dynamic series, an obser-
ver manually placed a circular region of interest (ROI) in
the LV blood pool depicted on a basal slice to obtain the
time-signal intensity plot of the arterial input function.
The ROI was then copied to the other dynamic images of
the same slice, the positions reviewed and manually
adjusted to correct for respiratory motion during data
acquisition if required. In the time-signal intensity plot
(Figure 5), we defined several time points of interest from
the arterial input function curve namely: dilute start point
(T dilute start), dilute peak point (T dilute peak) and dilute end
point (T dilute end). T dilute end was specified the time point
as; (T dilute peak-Tdilute start)+Tdilute peak. The time width
of dilute CA bolus curve (TW dilute) was defined as T dilute
end -Tdilute start (Figure 5). If TW dilute was shorter than
the predefined pause, this was regarded as an overlap
between the AIF curves of the dilute and neat CA bolus.
Table 1 Scan parameters of the saturation-recovery perfusion CMR sequences
Sequences Manufacturer Magnetic field strength Delay between saturation preparation
pulse and center of k-space
TR (ms) TE (ms) FA (°)
TFE Philips 3.0 105 3.6 1.7 18
k-t accelerated TFE Philips 3.0 110 2.7 0.9 20
TFE Philips 1.5 100 3.8 1.8 18
b-TFE Philips 1.5 100 2.5 1.2 50
k-t accelerated b-TFE Philips 1.5 100 2.9 1.5 50
TurboFLASH SIEMENS 1.5 255 156 1.13 12
(TR = repetition time, TE = echo time, FA = flip angle, TFE = turbo field echo, b-TFE = balanced TFE, k-t = k-space and time, TurboFLASH = turbo fast low-angle
shot)
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Page 7 of 13This would affect the quantitative analysis negatively. The
relationship between TW dilute and cardiac output was
obtained in 36 patients who underwent stress and
rest dual bolus perfusion s c a nu s i n g0 . 1m m o l / k go f
Gd-DO3A-butrol (1 mol/L).
Statistics
Linear regression analysis was performed in the 36
patients who underwent stress and rest dual bolus per-
fusion scan using 0.1 mmol/kg of Gd-DO3A-butrol
(1 mol/L) to evaluate the correlation of cardiac output
and TW dilute using MedCalc, version 11.4, software
(MedCalc Software bvba, Mariakerke, Belgium). For all
continuous parameters, results are given as the mean ±
standard deviation. A p value of less than 0.05 was con-
sidered as statistically significant.
Results
130 dual-bolus perfusion scans were performed in 70
patients at the original site where the dual-bolus scheme
was devised. 31 scans in a further 16 patients were sub-
sequently completed at 3 different sites. In total 161
dual-bolus perfusion scans were performed, 41 (25%) of
these were performed using a dual-head power injector
with a “pause” function. Three technical errors (1.9%)
were observed in the 161 perfusion scans. Two of three
errors were observed at the original site. In these two
cases, the dilute contrast was confused with neat one
resulting in the neat bolus being administered first. The
remaining error was observed at a remote site, the most
likely cause was related to manual injection of dilute
contrast into the extension tube at a wrong time. No
power injector related errors were observed. Apart from
these 3 errors, all dual-bolus perfusion scans were suc-
cessfully completed. The preparation time for the dual-
bolus set-up was 6.9 ± 1.5 min.
For all patients, EF and heart rate at rest and during
stress were 57 ± 15% (range 81-16%), 68 ± 13 beat/min
(range 43-106 beat/min) and 90 ± 17 beat/min (range
48- 167 beat/min), respectively. Cardiac output was
5.6 ± 1.5 L/min (range 9.6-2.4 L/min) at rest and 7.4 ±
2.1 L/min (range 3.4-14.0 L/min) during stress.
Linear regression analysis showed a moderate correlation
between TW dilute and cardiac output (y = -1.2978 × +
22.559, r = 0.511, p < 0.001) (Figure 6). This plot also indi-
cated that 25s is the optimal duration for the predefined
pause despite one outlier who was a patient with low car-
diac output. TW dilute at rest was significantly longer than
TW dilute during stress (15.6 ± 4.6s vs 11.8 ± 4.2s, p <
0.001).
The dual-bolus scheme worked well if the appropriate
predefined pause was selected for any of the following
Table 2 Number of dual-bolus perfusion scans (patients) in which different kinds and doses of gadolinium contrast
agent, manufacturers and perfusion sequences were used
Gd-DO3A-butrol 1.0 mol/L Philips 3.0T
Dose (mmol/kg) TFE k-t accelerated TFE
0.025 28 (14) -
0.075 - 1 (1)
0.1 - 4 (2)
Gd-DO3A-butrol 1.0 mol/L Philips 1.5T
Dose (mmol/kg) TFE b-TFE k-t accelerated b-TFE
0.025 4 (2) - -
0.075 2 (2) - 19 (11)
0.1 - - 37 (19)
0.1 - 2 (2) 33 (18)
Gd-DO3A-butrol 1.0 mol/L SIEMENS 1.5T
Dose (mmol/kg) TurboFLASH
0.05 6 (3)
0.075 3 (2)
Gd-DTPA 0.5 mol/L Philips 1.5T
Dose (mmol/kg) b-TFE
0.05 10 (5)
Gd-DOTA 0.5 mol/L Philips 1.5T
Dose (mmol/kg) b-TFE
0.1 12 (6)
(TFE = turbo field echo, b-TFE = balanced TFE, k-t = k-space and time, TurboFLASH = turbo fast low-angle shot)
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Page 8 of 13conditions: three different contrast agents (Gd-DO3A-
butrol, 1 mol/L; Gd-DTPA, 0.5 mol/L; Gd-DOTA 0.5
mol/L), 4 different doses (0.025 mmol/kg, 0.05 mmol/
kg, 0.075 mmol/kg, 0.1 mmol/kg), 2 different types of
injectors (with and without “pause” function) and 3
different MR scanners from 2 different manufacturers
(Philips Acheiva and Intera; Siemens Avanto) (Figure 7).
There was 1 patient with hyper contractile LV func-
tion (EF >80%) and 5 patients with low LV function (EF
< 30%) in this study patient population (Figure 8). In all
patients with an EF < 30% the time-signal intensity
curves showed an overlap between the dilute and neat
CA bolus curves regardless of the duration of the prede-
fined pause. In contrast there was excellent separation
of the two curves in the case with hyper contractile LV
function.
Discussion
The universal dual-bolus injection scheme proposed in
the present paper has several advantages. Firstly, this
method is not dependent on sophisticated function of a
double-head power injector. The latest dual-head power
injectors have variable functions such as a multiple
injection phase, a “pause” phase, a “hold” phase and so
on. In some newer injectors, it is even possible to selec-
tively inject gadolinium CA or saline interchangeably.
However, most of the power injectors widely available
for clinical CMR have only two injection phases for
each injector head and no “pause” or “hold” phase. The
order of contrast injection and saline injection cannot
be programmed in these injectors. With these injectors,
if the syringes on the injector heads are set up in the
usual way and filled with contrast media for the first
Figure 5 In the time-signal intensity plot, several time frames of interest from arterial input function curve are indicated: dilute
start frame (T dilute start), dilute peak frame (T dilute peak), dilute end frame (T dilute end), neat start frame (T neat start).Tdilute end was
specified the time point as; (T dilute peak-Tdilute start)+Tdilute peak. The time width of dilute CA bolus curve (TW dilute) was defined as T dilute end -
T dilute start.
Figure 6 Linear regression analysis showed a moderate
correlation between TW dilute and cardiac output in the group
A (0.1 mmol/kg of Gd-DO3A-butrol, n = 36) (y = -1.2978x +
22.559, r = 0.511, p < 0.001). This graph also indicated that 25s is
the optimal duration for the predefined pause despite of one
outlier in the patient with low cardiac output.
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Page 9 of 13Figure 7 Raw time-signal intensity curves for dual-bolus first-pass perfusion MR imaging of LV blood pool are illustrated for the
following each condition: (A: 3.0T, Gd-DO3-butrol, 0.025 mmol/kg, TFE, Philips, Stress, B: 3.0T, Gd-DO3-butrol, 0.075 mmol/kg, k-t TFE, Philips,
rest, C: 3.0T, Gd-DO3-butrol, 0.1 mmol/kg, k-t TFE, Philips, rest, D: 1.5T, Gd-DO3-butrol, 0.075 mmol/kg, k-t b-TFE, Philips, rest, E: 1.5T, Gd-DO3-
butrol, 0.1 mmol/kg, b-TFE, Philips, rest, F: 1.5T, Gd-DO3-butrol, 0.1 mmol/kg, b-TFE, Philips, stress, G: 1.5T, Gd-DO3-butrol, 0.075 mmol/kg, TFE,
Philips, rest, H:1.5T, Gd-DO3-butrol, 0.1 mmol/kg, k-t b-TFE, Philips, rest, I: 1.5T, Gd-DO3-butrol, 0.1 mmol/kg, k-t b-TFE, Philips, stress, J: 1.5T, Gd-
DO3-butrol, 0.05 mmol/kg, TurboFLASH, SIEMENS, rest, K: 1.5T, Gd-DO3-butrol, 0.1 mmol/kg, k-t b-TFE, Philips, rest, L: 1.5T, Gd-DO3-butrol, 0.1
mmol/kg, k-t b-TFE, Philips, stress, M: 1.5T, Gd-DO3-butrol, 0.075 mmol/kg, TurboFLASH, SIEMENS, rest, N: 1.5T, Gd-DO3-butrol, 0.075 mmol/kg, k-t
b-TFE, TFE, Philips, rest, O: 1.5T, Gd-DO3-butrol, 0.075 mmol/kg, k-t b-TFE, TFE, Philips, stress, P: 1.5T, Gd-DO3-butrol, 0.025 mmol/kg, TFE, Philips,
rest, Q: 1.5T, Gd-DOTA, 0.1 mmol/kg, b-TFE, Philips, stress, R: 1.5T, Gd-DTPA, 0.05 mmol/kg, b-TFE, Philips, stress (magnetic field strength, kind of
gadolinium CA, dose of gadolinium CA, sequence, manufacturer and rest or stress, respectively)). Two peaks were cascaded to produce a
continuous time-signal intensity plot: a lower peak after 10%-dilute contrast administration, followed by a higher peak after neat contrast
administration. Figure 5E and 5F, 5H and 5I, 5K and 5L and 5N and 5O are the signal-intensity curves for rest and stress perfusion obtained in
the same session. These graphs show that this dual-bolus approach has a good reproducibility in the same CMR session for rest and stress
perfusion.
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Page 10 of 13injection and saline for the second injection, it is com-
plex to inject the dilute contrast medium and neat gado-
linium CA serially and impossible to program the
temporal delay between each bolus. In the present
study, we used 2 different double-head injectors with
and without a “pause” phase and found no injector
related errors. The dual-bolus injection scheme
described in this article provides a practical, straightfor-
ward and robust solution even for standard injectors.
Secondly, using this method of manually injecting the
contrast agent into the tube just before the injection,
the dual bolus can be easily and reliably repeated in
every CMR perfusion scan. Repeatability of the dual-
bolus method is important in clinical assessment of
ischemic heart disease because both stress and rest
perfusion CMR are done in the same session. In the
current study, 2 remote and 1 local site demonstrated
that this dual-bolus scheme can be easily and reliably
repeated. Both sites completed successful dual-bolus
perfusion scans with minimal training. Although Chris-
tian TF et al performed similar methods for their dual-
bolus method in their animal study, they did not repeat
the dual-bolus injection in the same session(8). Recently
we have proposed an isolated perfused pig heart model
for novel sequence development(13). This model is well
controlled, offers exact titration of coronary blood flow
and has also proven amenable for perfusion imaging
using the dual bolus contrast injection scheme. The par-
ticular advantage of the pig heart model is that one can
perform multiple perfusion scans in a single heart. It is
Figure 8 Time-signal intensity curves for dual-bolus perfusion scan at rest in a patient with hyper contractile LV EF (>80%) (a) and
with low LV EF (<30%) (b, c, d, e, f) are shown. The information under each curve is ordered as EF, contrast agent, dose, predefined pause,
CO (EF: ejection fraction, CO: cardiac output). In the patient with hyper contractile LV EF, two curves, namely, dilute and neat CA bolus, are well
separated. However, in the patients with low LV EF, these two curves are overlapped with a various extent regardless of CA dose and predefined
pause duration.
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approaches for quantification of myocardial blood flow
before translating those methods to patients. Ritter et al
quantified stress and rest MBF by perfusion CMR in
healthy volunteers with the pre-bolus technique (14).
However, practically the pre-bolus technique requires a
different set up because this technique uses 1 ml of
undiluted contrast medium for the first bolus to deter-
mine the arterial input function. This pre-bolus techni-
que also requires different post processing to construct
the AIF from the pre-bolus time-intensity curve. There
is only a single study by Utz et al. which applied a dual-
bolus technique to stress and rest perfusion CMR in
patients (9). However, although they demonstrated
improved accuracy for absolute MBF values compared
to the single-bolus approach, the details of the dual-
bolus injection scheme are not provided. Thirdly, this
dual-bolus injection scheme can be performed without
any new, unusual or expensive materials or techniques.
The only material required in addition to the normal
set-up are extension tubes, 3-way stopcocks and syringes
which are all widely available.
The regression analysis obtained in this study sug-
gested that optimal predefined pause duration between
the dilute and neat gadolinium injection is 25 seconds
or more if a contrast agent with high gadolinium con-
centration (1 mol/L) is used. Cardiac output had a nega-
tive but only moderate correlation with time width of
the dilute CA curve and the time width of the dilute CA
curve was significantly longer in the resting state than
during stress. These finding suggest that the predefined
pause should be prolonged for the rest perfusion scan if
there was any overlap of the curves at stress. Theoreti-
cally, using a lower concentration of gadolinium con-
trast agent (e.g. 0.5 mol/L), the bolus profile should be
wider than in the case of higher concentration of gadoli-
nium contrast agent (e.g. 1.0 mol/L) because the weight
dependent volume of contrast agent given to the patient
is larger (e.g. If the patient’sb o d yw e i g h ti s6 0k ga n d
dose of gadolinium contrast is 0.1 mmol/kg, 6 ml of
Gd-DO3A-butrol is administered which is equivalent to
12 ml of Gd-DTPA). Therefore, a longer pause between
the two injections should be used.
The current approach requires substantial “user” inter-
action. In the present study, there were 3 technical
errors, in two cases the dilute gadolinium agent and the
neat contrast agent syringes were confused. A repetition
of these errors was avoided by carefully labelling each
syringe. Another error was observed at a remote site
and related to the manual contrast injection at a wrong
time. This occurred during one of the first studies and
might be explained by relative inexperience with the
method. Undergoing some simple and brief training
before applying our methods during clinical scanning
should overcome such “user” related problems. This
dual-bolus injection scheme requires 6.9 ± 1.5 minutes
for the preparation of gadolinium contrast agent and the
set-up for power injector and lines. However, the perfu-
sion scan is only extended by the duration of the prede-
fined pause (i.e. ~25s in each perfusion scan). In our
institute, standard stress-rest myocardial perfusion CMR
set-up with normal single bolus injection scheme
requires 3.2 ± 1.8 minutes for the preparation of gadoli-
nium contrast agent and the set-up for power injector
and lines. The dual-bolus injection scheme needs just a
few more minutes on top of the normal set-up
In patients with low LV function (EF < 30%), the dual-
bolus curves tend to overlap due to low cardiac output.
In these cases, a longer predefined pause is required.
Further investigation is required to ascertain whether
the poor bolus profile in these patients still provides
diagnostic and accurate MBF quantification. In contrast,
our dual-bolus scheme worked well in a patient with LV
EF of > 80%.
Only adenosine was tested as a pharmacological stress
agent in the present paper. Recently, the Food and Drug
Administration approved regadenoson for stress testing
in conjunction with myocardial perfusion imaging(15).
Regadenoson, unlike adenosine, is a selective A2A ago-
nist that is given as an intravenous bolus at a fixed dose
and causes myocardial blood flow and heart rate to peak
shortly after injection followed by a slow reduction in
myocardial blood flow and a decreasing heart rate after
approximately 2 minutes. Potentially, this dual-bolus
scheme can be applied to regadenosone if the timing of
bolus injection of contrast agent and regadenosone is
optimized. Further studies will be required to show that
this practical dual-bolus approach works for this new
vasodilator stress agent.
Limitation
We would like to acknowledge the main limitation of
this study. Inevitably the use of a manual contrast injec-
tion necessitates the presence of a physician within the
MR scanner room at the time of injection. However, the
presence of a physician is reassuring for the patient par-
ticularly during the stress perfusion.
Conclusion
We have devised a universal dual-bolus injection
scheme, for use in a clinical setting, that is independent
of sophisticated double-head power injector function.
The universal dual-bolus injection scheme is a feasible
technique to obtain a reasonable arterial input function
curve to calculate absolute quantification of myocardial
blood flow.
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